Yamamoto N, Kamitani T, Kanda K, Ito Y, et al. Real-world Outcomes of Pembrolizumab Monotherapy in Non-Small Cell Lung Cancer in Japan: a Post-marketing Surveillance. Cancer Sci 2022 May 24. doi: 10.1111/cas.15439.
PMID: 35611470